Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265635 | 0.87 | TAAR1 (0.68) | TAAR1GAABACE1KDM4EHTT | |
| SCHEMBL2199784 | 0.84 | TAAR1 (0.63) | TAAR1GAABACE1KDM4EHTT | |
| SCHEMBL110369 | 0.83 | AKR1B1 (0.52) | TAAR1GAAHTTMAPTKMT2A | |
| SCHEMBL113326 | 0.83 | TAAR1 (0.48) | TAAR1GAABACE1KDM4EMAPT | |
| SCHEMBL3455236 | 0.80 | TAAR1 (0.77) | TAAR1GAABACE1KDM4EHTT | |
| SCHEMBL3115865 | 0.80 | TAAR1 (0.70) | TAAR1GAABACE1KDM4EHTT | |
| SCHEMBL1197584 | 0.80 | TAAR1 (1.00) | TAAR1GAABACE1KDM4EHTT | |
| SCHEMBL30776827 | 0.79 | TAAR1 (0.63) | TAAR1GAABACE1KDM4EHTT | |
| SCHEMBL28596017 | 0.79 | TAAR1 (0.63) | TAAR1GAABACE1KDM4EHTT | |
| SCHEMBL601569 | 0.79 | TAAR1 (0.63) | TAAR1GAABACE1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | claimed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | claimed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-0979812-B1 | Process for the preparation of fluorinated benzyl alcools and benzyl aldehydes | BAYER AG (DE) | 2003-10-29 | — | — | EP | claimed |
| EP-0979812-A1 | Process for the preparation of fluorinated benzyl alcools and benzyl aldehydes | Bayer Aktiengesellschaft (DE) | 2000-02-16 | — | — | EP | claimed |
| US-5922117-A | Ink compositions containing alcohols | XEROX CORPORATION (US) | 1999-07-13 | — | — | US | claimed |
| US-5354495-A | Homo- or copolymerizable through ethylenic unsaturation | NIPPON PAINT CO., LTD. (JP) | 1994-10-11 | — | — | US | claimed |
| EP-0177122-B1 | ACRYLAMIDE DERIVATIVES | Nippon Paint Co., Ltd. (JP) | 1992-04-01 | — | — | EP | claimed |
| US-4935413-A | ELASTICITY, ADHESION AND DISPERSIBILITY | NIPPON PAINT CO., LTD. (JP) | 1990-06-19 | — | — | US | claimed |
| CN-119972172-A | Heterogeneous organic polymer catalyst, preparation method thereof and method for synthesizing aldehyde or lactone compound | 武汉光化学技术研究院 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230295087-A1 | AGONISTS OF ROR GAMMAt | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| EP-0057795-B1 | HALOBENZYL ESTERS OF HALOALKENYLCYCLOPROPANE ACIDS, THEIR PREPARATION, COMPOSITIONS AND METHOD OF COMBATING INSECT PESTS THEREWITH | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-07-10 | — | — | EP | disclosed |
| EP-0126875-A1 | Light-sensitive polycondensation product with diazonium groups, process for the preparation thereof and light-sensitive registration material which contains this polycondensation product | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-12-05 | — | — | EP | disclosed |
| EP-0093010-A2 | Alpha-hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-11-02 | — | — | EP | disclosed |
| EP-0060617-A1 | Fluorobenzyl cyclopropane carboxylates, their preparation, compositions and use as insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-09-22 | — | — | EP | disclosed |
| EP-0057795-A1 | Halobenzyl esters of haloalkenylcyclopropane acids, their preparation, compositions and method of combating insect pests therewith | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | TAAR1 789/4885GAA 2715/4885BACE1 1/4885 |
| US-20230295087-A1 | AGONISTS OF ROR GAMMAt | RORB, RORA, RORC | TAAR1 458/4885GAA 1445/4885BACE1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.